rimabotulinumtoxinB clinical trials
Also written MYOBLOC and botulinum toxin type B.
How each study uses rimabotulinumtoxinB is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 8 Dec 2000 · MYOBLOC · BLA 103846 (FDA, Drugs@FDA)
- European Union
- 22 Jan 2001 · NeuroBloc · EMEA/H/C/000301 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 9
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (4) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (3) · Gunma University (1) · University Hospital of North Norway (1) · Georgetown University (1) · Columbia University (1) · Eisai Co., Ltd. (1) · Eisai Limited (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rimabotulinumtoxinB is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb SpasticityTerminatedPhase 2/3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT04815967Written as Phase 2; Low Dose MYOBLOC (10,000 Units)How we know
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb SpasticityTerminatedPhase 2/3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT04099667Written as Phase 2; Low Dose MYOBLOC (15,000 Units)How we know
- Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical DystoniaCompletedPhase 4Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT00702754Written as Botulinum Toxin Type BHow we know
- Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in AdultsCompletedPhase 3Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT02610868Written as MYOBLOCHow we know
- A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease PatientsCompletedPhase 2Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT00515437Written as Botulinum Toxin Type B (Myobloc)How we know
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult SubjectsCompletedPhase 3Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT01994109Written as MYOBLOCHow we know
- Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric SubjectsWithdrawnPhase 3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT05097079Written as MYOBLOC Low DoseHow we know
- Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic SclerosisCompletedPhase 2Gunma UniversityNCT03007004Written as Botulinum toxin type B (2500 units / vial)How we know
- Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis SuppurativaCompletedNot applicableUniversity Hospital of North NorwayNCT03103074Written as Botulinum B ToxinHow we know
- Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal HyperhidrosisStatus unknownPhase 2Carl SwartlingNCT01930604Written as NeuroBloc/Myobloc (rimabotulinumtoxinB)How we know
- Myobloc Atrophy StudyCompletedPhase 4Georgetown UniversityNCT02052024Written as MYOBLOCHow we know
- Quantifying Musical Performance After Treatment With Myobloc in Musician's DystoniaCompletedPhase 4Columbia UniversityNCT00208091Written as Botulinum toxin, type BHow we know
- Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic TorticollisCompletedPhase 2Eisai Co., Ltd.NCT00165776Written as BOTULINUM TOXIN TYPE BHow we know
- An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian SubjectsCompletedPhase 2Eisai LimitedNCT00280384Written as E2014 (Botulinum toxin type B)How we know
- Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated SweatingCompletedPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT01671800Written as Botulinum Type BHow we know
- Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2/3The University of Texas Health Science Center at San AntonioNCT00125203Written as Botulinum toxin type B (Myobloc)How we know
- Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back PainTerminatedPhase 4United States Department of DefenseNCT00384579Written as Botulinum toxin BHow we know
- "DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?"CompletedPhase 1/2Stanford UniversityNCT00238641Written as Botulinum Toxin type BHow we know
Codes
What other systems call rimabotulinumtoxinB · ClinicalTrials.gg INT003872
- MeSH (NLM) C096323rimabotulinumtoxinBConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0Y70779M1FRIMABOTULINUMTOXINBConfirmed FDA, NLM
- RxNorm 860178One source FDA
- NCI Thesaurus C87453RimabotulinumtoxinbOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C096323 | rimabotulinumtoxinB | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0Y70779M1F | RIMABOTULINUMTOXINB | Confirmed FDA, NLM |
| RxNorm | 860178 | — | One source FDA |
| NCI Thesaurus | C87453 | Rimabotulinumtoxinb | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.